The Role of NK Cells in the Immune Response to HIV Infection
Population-level genetic associations between NK cell receptor expression and HIV-1 outcomes and evolution reveal the impact of NK cells on HIV-1 disease progression. The germline encoded inhibitory receptors including the killer immunoglobulin-like receptors (KIRs) heavily influence NK cell activation which is governed by the integration of activating and inhibitory signals. Interactions between KIRs and their cognate HLA ligands set a threshold for NK activity and have been shown to critically influence the course of viral infection, associating with resolution of hepatitis C infection [
17]. In HIV, HLA/KIR combinations have been associated with the pace of disease progression [
18,
19] and protection against disease acquisition [
20,
21]. The mechanisms conferring this protection may include both NK cell education/licensing through inhibitory receptor ligation [
22] and the direct interaction of KIRs with HIV-1-derived peptide motifs presented on HLA molecules. The latter is supported by virus evolution in the presence of specific KIRs; footprints in the HIV genome associate with KIR genotype. Specific viral variant/KIR combinations associate with differences in NK cell viral inhibition in vitro [
23] and HLA/KIR combinations confer differences in HIV control [
24]. The HLA/KIR interactions directed by specific HIV-derived peptides are further linked to measures of NK cell function in vitro and patterns of viral escape in population studies [
25,
26]. These data suggest that NK cell activation threshold, determined in part by the genetic array of inhibitory receptors, and the virus-derived peptides available for presentation on host HLA cooperate to define the protective efficacy of NK cell responses. The latter could be exploited to harness function; computation approaches may be able to predict peptides that modulate NK function based on host HLA/KIR patterns to individualize vaccine design.
These data demonstrate direct interactions between NK cells and HIV peptides; however, it is not known whether these signals govern in vivo effector function and which of the overlapping recognition pathways is sufficient for an effective response. Although counterintuitive, focusing on immune responses that HIV has evolved to evade may point to highly effective means of NK activation. HIV-mediated downregulation of HLA molecules, which shields infected cells from killing by CD8
+ T cells [
27], theoretically offers the “missing self” trigger for NK cells. However, this is limited by HIV immune evasion; the downregulation of HLA A and B by Nef is coupled to preservation of HLA C and E, maintaining self signals, and preventing NK activation [
28]. Likewise, HIV infection directly triggers the upregulation of stress ligands for cytotoxicity receptors including NKG2D [
29,
30]. Again, HIV is able to limit expression of these ligands and other coactivating signals such as NTBA-4 through accessory proteins [
29,
31]. While the precise contribution of each activation pathway in natural infection is difficult to prove, from the perspective of prevention and cure, each could be leveraged to optimize responses. Small molecule inhibitors disabling immune evasion through viral accessory proteins may enhance native or vaccine-induced immune recognition.
ADCC is a potent means of NK cell control of HIV-1 infection. NK cells express the FcγRIIIA receptor (CD16) that binds the constant (Fc) domain of IgG antibodies. CD16 engagement is a strong activator of NK cell function, and allows antigen-specific recruitment of NK responses. Importantly, ADCC activity was associated with the modest protective efficacy in the RV144 HIV vaccine trial [
6] and has been implicated in phenotypes of viral control [
32,
33]. Responses characterized by coordinated antibody function, including NK mediated ADCC and NK cytokine secretion/degranulation associated with viral controller phenotypes [
34]. ADCC efficiency is linked to specific antibody features including subclass and glycosylation that can be modified to enhance NK cell recruitment and activation. NK cell maturation and education can further enhance HIV-specific ADCC activity [
35,
36]. Of note, as with other effector pathways, ADCC is also limited by viral evasion: the viral accessory protein Vpu antagonizes the antiviral factor tetherin, altering the release of virus aggregates and disabling ADCC mediated viral recognition [
37‐
41]. A small molecule inhibitor of vpu’s interaction with tetherin has recently been described suggesting an additional target for intervention [
42]. An optimized approach would prime NK cells, induce antibodies with glycan and subclass features maximized for ADCC and could potentially be coupled with pharmacologic blockade of viral immune evasion to further enhance antiviral function.
The collective data highlight the importance of NK cells in HIV disease. There are multiple pathways for target elimination, all balanced by mechanisms of viral evasion that define kinetic windows of maximal response and opportunities for enhancement. In addition to these specific interactions, NK cell recognition of generic signals of stress and infection induced early in HIV infection is an important area for exploration. Optimized NK cell function can be achieved through directly augmenting NK cell function with priming and subset expansion or inhibitory receptor blockade, indirectly through optimization of antibodies to recruit NK cells, and potentially also through blockade of viral accessory proteins to limit immune evasion.
The Consequences of HIV Infection for NK Cell Distribution and Function
Chronic HIV-1 infection alters the population distribution and functional capacity of NK cells. Numerous studies have described these changes in the setting of HIV infection and have at times produced diverging and contradictory results. This lack of clarity is likely related to multiple factors: the dependence of NK cell function on the associated HLA genotype has not always been fully considered, many studies are cross sectional in nature and may not have adequately controlled for confounders between groups including CMV serostatus, age, and gender, and finally the diversity of NK cell phenotypes is not fully captured in a limited examination of markers [
11,
12••].
NK cells are divided into subsets based on their expression of CD56 and CD16; these subsets are thought to represent stages in NK cell differentiation, although the precise relationship has not been fully defined. Based on immunodeficiency syndromes, both CD56
bright and CD56
dim populations contribute to antiviral immunity. CD56
brightCD16
− cells are a minor population in healthy individuals with relatively limited cytotoxic capacity but strong production of cytokines. CD56
dim NK cells are the majority of the circulating population with less proliferative potential, increased cytotoxic capacity, and progressive acquisition of KIRs and markers including CD57 during differentiation. A third minor population is the CD56
neg NK cells that are CD16
+; these cells have been difficult to characterize with their limited expression of lineage markers. NK cells express a broad complement of additional receptors including the predominantly inhibitory KIRs; the natural cytotoxicity receptors (NCRs) including NKp30, NKp44, and NKp46; the C-type lectin receptors including NKG2D, NKG2C, and NKG2A; signaling lymphocyte activation (SLAM) family receptors as well as the Fcγ receptor CD16 [
43]. NK cell degranulation/cytotoxicity and cytokine secretion are governed by the overall balance of activating and inhibitory signals, with an important role for education through inhibitory signaling during development [
44]. The roles of each subset in HIV-1 infection are still being defined.
During primary HIV infection, initiation of antiretroviral therapy was associated with reciprocal variation in the CD16
+CD56
dim and CD56
high NK cells, with the latter, more immature population, increasing after therapy [
45]. Initiation of therapy also changes immunoregulatory markers; modulation of galectin 9 and T cell immunoglobulin and mucin-domain containing molecule-3 (TIM-3) in early infection leads to enhanced NK cell activity, but in chronic HIV the interaction may contribute to NK cell dysfunction [
46]. Dysregulated TIM-3 expression on NK cells is linked to impaired CD4 recovery after treatment, suggesting that NK cell dysfunction may contribute to a poor immunologic reconstitution in some individuals [
47]. CD56
negCD16
+ cells with reduced ADCC activity also accumulate during chronic infection, a defect that is significantly restored with viral suppression [
48,
49]. Counterbalancing this restoration of NK cell ADCC is the decline in antibody conferred activity after initiation of antiretroviral therapy (ART) [
50]. Thus, to fully exploit the potential for NK cell-mediated function in cure/eradication strategies through ADCC, restoration of subset distribution is an essential step, beyond optimizing antibody subclass, glycan structure and titer through vaccination or administration of a monoclonal.
In vitro studies have sought to dissect receptor patterns that lead to NK cell control of HIV infection. When exposed to infected CD4
+ T cells, autologous NK cells expressing NKG2A responded with CD107a (a marker of degranulation), IFNγ, and CCL4 at the highest frequencies [
51]. Profiling the NKG2A receptor expression in an individual may offer an index of their likelihood to have an effective NK cell response to a therapeutic intervention. In the setting of significant inflammation in a cohort in Uganda with HIV subtype D infection, impaired effector function (IFNγ production) and loss of a highly activated subset of NK cells has been described [
52]. Further evidence of dysfunction is suggested by studies in the SIV nonhuman primate model demonstrating anergic NK cell accumulation in lymph nodes in chronic infection [
53]. Research to redirect or rescue function will be informed by the more complete understanding of the pathology of HIV. An alternative window to identify highly effective activation pathways may be through the enhanced effector capability seen in NK cells from individuals with spontaneous viral control. One recent example is the recent report of a potential role for NK cells in the long-term suppression of HIV-1 in the VISCONTI cohort of post-treatment controllers (Scott-Algara, et al., Abstract 15,CROI 2015, Seattle, WA).
In support of the concept that NK cells can be directed, methods of bolstering NK cell functional capacity in HIV infection have been described. A therapeutic HIV vaccine that restored CD4
+ T cell IL-2 production led to enhanced production of IFNγ by NK cells [
54]. Secretion of IFNα by other cells drives NK cell activation and lysis of HIV-infected CD4
+ T cells through NKp46- and NKG2D-mediated signaling [
55]. The cross-talk between adaptive and NK cell responses is a critical means for optimizing NK cell function. Coordinating the recruitment and activity of multiple cell types, particularly in the setting of an inflamed and anergic immune system, may be the key to promoting more effective NK cell control of HIV.